{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:18:19Z","timestamp":1790936299513,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","aaojournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ophtha.2016.12.025","type":"journal-article","created":{"date-parts":[[2017,3,22]],"date-time":"2017-03-22T02:05:51Z","timestamp":1490148351000},"page":"619-633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":141,"title":["Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity"],"prefix":"10.1016","volume":"124","author":[{"given":"Deborah K.","family":"VanderVeen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Melia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy K.","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorri B.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2016.12.025_bib1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10456-007-9066-0","article-title":"Retinopathy of prematurity","volume":"10","author":"Chen","year":"2007","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ophtha.2016.12.025_bib2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ophtha.2014.07.050","article-title":"Pathophysiology and mechanisms of severe retinopathy of prematurity","volume":"122","author":"Hartnett","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.12.025_bib3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2165\/00128072-200103040-00003","article-title":"The management of retinopathy of prematurity","volume":"3","author":"Reynolds","year":"2001","journal-title":"Paediatr Drugs"},{"issue":"Suppl 1","key":"10.1016\/j.ophtha.2016.12.025_bib4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/pr.2013.205","article-title":"Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010","volume":"74","author":"Blencowe","year":"2013","journal-title":"Pediatr Res"},{"key":"10.1016\/j.ophtha.2016.12.025_bib5","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/archopht.1988.01060130517027","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results","volume":"106","year":"1988","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.12.025_bib6","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.12.025_bib7","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1073\/pnas.92.3.905","article-title":"Vascular endothelial growth factor\/vascular permeability factor expression in a mouse model of retinal neovascularization","volume":"92","author":"Pierce","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2016.12.025_bib8","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1001\/archopht.1996.01100140419009","article-title":"Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity","volume":"114","author":"Pierce","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.12.025_bib9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000087587","article-title":"IGF-1 and retinopathy of prematurity in the preterm infant","volume":"88","author":"Smith","year":"2005","journal-title":"Biol Neonate"},{"key":"10.1016\/j.ophtha.2016.12.025_bib10","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.ophtha.2007.08.050","article-title":"Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity","volume":"115","author":"Sonmez","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.12.025_bib11","doi-asserted-by":"publisher","first-page":"947","DOI":"10.2147\/OPTH.S11650","article-title":"Intraocular and systemic levels of vascular endothelial growth factor in advanced cases of retinopathy of prematurity","volume":"4","author":"Velez-Montoya","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.12.025_bib12","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders","volume":"331","author":"Aiello","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2016.12.025_bib13","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1111\/j.1651-2227.2011.02445.x","article-title":"On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment\u2014a review","volume":"100","author":"H\u00e5rd","year":"2011","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.ophtha.2016.12.025_bib14","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The International Classification of Retinopathy of Prematurity revisited","volume":"123","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.12.025_bib15","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2016.12.025_bib16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.5301\/ejo.5000166","article-title":"Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II","volume":"22","author":"Autrata","year":"2012","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.12.025_bib17","doi-asserted-by":"publisher","first-page":"e496","DOI":"10.1111\/aos.12339","article-title":"Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity","volume":"92","author":"Moran","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.12.025_bib18","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.12.025_bib19","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","article-title":"Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings","volume":"121","author":"Lepore","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.12.025_bib20","unstructured":"Zhang G, Yang M, Zeng J, et\u00a0al; Shenzhen Screening for Retinopathy of Prematurity Cooperative Group. Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity. Retina. 2016 Aug 12. [Epub ahead of print.]"},{"key":"10.1016\/j.ophtha.2016.12.025_bib21","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s00417-010-1375-0","article-title":"Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels","volume":"248","author":"Lee","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.12.025_bib22","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.ajo.2013.01.014","article-title":"Intravitreal bevacizumab for retinopathy of prematurity: refractive error results","volume":"155","author":"Harder","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.12.025_bib23","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","article-title":"Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis","volume":"122","author":"Hwang","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.12.025_bib24","first-page":"140","article-title":"Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser","volume":"19","author":"Isaac","year":"2015","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.ophtha.2016.12.025_bib25","first-page":"1","article-title":"Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey","volume":"15","author":"Gunay","year":"2016","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ophtha.2016.12.025_bib26","doi-asserted-by":"publisher","first-page":"e0161692","DOI":"10.1371\/journal.pone.0161692","article-title":"Characteristics of severe retinopathy of prematurity in infants with birth weight above 1500 grams at a referral center in Turkey","volume":"11","author":"Gunay","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ophtha.2016.12.025_bib27","doi-asserted-by":"publisher","unstructured":"Mueller B, Salchow DJ, Waffenschmidt E, et\u00a0al. Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone. Br J Ophthalmol. 2016 Jun 14. pii: bjophthalmol-2016\u2013308375. doi:10.1136\/bjophthalmol-2016-308375. [Epub ahead of print.]","DOI":"10.1136\/bjophthalmol-2016-308375"},{"key":"10.1016\/j.ophtha.2016.12.025_bib28","unstructured":"University of Texas Health Science Center, Houston. Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT-ROP). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00622726. Accessed September 27, 2016."},{"key":"10.1016\/j.ophtha.2016.12.025_bib29","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ajo.2012.06.010","article-title":"An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan","volume":"155","author":"Wu","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.12.025_bib30","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s00417-014-2867-0","article-title":"Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity\u201427 month follow-up results from Turkey","volume":"253","author":"Yetik","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.12.025_bib31","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","article-title":"Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between ranibizumab and bevacizumab","volume":"35","author":"Chen","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2016.12.025_bib32","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3928\/23258160-20160419-16","article-title":"Current practice patterns for treatment of retinopathy of prematurity","volume":"47","author":"Tawse","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.ophtha.2016.12.025_bib33","doi-asserted-by":"publisher","first-page":"e744","DOI":"10.1111\/aos.13069","article-title":"The German ROP Registry: data from 90 infants treated for retinopathy of prematurity","volume":"94","author":"Walz","year":"2016","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.12.025_bib34","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","article-title":"Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy","volume":"123","author":"Mintz-Hittner","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.12.025_bib35","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","article-title":"Reactivation of retinopathy of prematurity after ranibizumab treatment","volume":"35","author":"Wong","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2016.12.025_bib36","doi-asserted-by":"publisher","first-page":"340","DOI":"10.5935\/0004-2749.20150090","article-title":"Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity","volume":"78","author":"Erol","year":"2015","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.ophtha.2016.12.025_bib37","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.12.025_bib38","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity","volume":"56","author":"Kong","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2016.12.025_bib39","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.12.025_bib40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00417-015-2996-0","article-title":"Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab","volume":"254","author":"Zhou","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.12.025_bib41","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3109\/02713683.2014.941070","article-title":"Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity","volume":"40","author":"Araz-Ersan","year":"2015","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ophtha.2016.12.025_bib42","doi-asserted-by":"publisher","first-page":"e0148019","DOI":"10.1371\/journal.pone.0148019","article-title":"Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment","volume":"11","author":"Lien","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ophtha.2016.12.025_bib43","doi-asserted-by":"publisher","first-page":"e20153218","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.ophtha.2016.12.025_bib44","unstructured":"Jaeb Center for Health Research. Phase 1 trial of bevacizumab treatment for severe retinopathy of prematurity (ROP1). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02390531?term=NCT02390531&rank=1. Accessed September 27, 2016."},{"key":"10.1016\/j.ophtha.2016.12.025_bib45","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","article-title":"Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD","volume":"98","author":"Avery","year":"2014","journal-title":"Br J Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642016324149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642016324149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T05:26:10Z","timestamp":1535952370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642016324149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0161642016324149"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2016.12.025","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2016.12.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}